Clinical Commissioning Policy Proposition:

Similar documents
Clinical Commissioning Policy Proposition:

DRAFT FOR CONSULTATION. Clinical Commissioning Policy Proposition: Palliative radiotherapy for bone pain

Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)

Clinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex

Reference: NHS England B01X26

Clinical Commissioning Policy Proposition:

Clinical Commissioning Policy Proposition: Pasireotide: An injectable medical therapy for the treatment of Cushing's disease

DRAFT FOR CONSULTATION. Clinical Commissioning Policy Proposition: Robotic assisted trans-oral surgery for throat and voice box cancers

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension

Clinical Commissioning Policy Proposition: Rituximab for cytopaenia complicating primary immunodeficiency

Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer

Clinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer

Clinical Commissioning Policy Proposition: Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults)

DRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)

Specialised Services Policy: CP22. Stereotactic Radiosurgery

Insert heading depending. cover options once. other cover options once you have chosen one. 20pt. Ref: N-SC/031

DRAFT FOR PUBLIC CONSULTATION. Clinical Commissioning Policy Proposition: Infliximab for the treatment of hidradenitis suppurativa

Clinical Commissioning Policy Proposition:

Clinical Commissioning Policy: Vagal Nerve Stimulation (VNS) December Reference : NHSCB/D4/c/7

Insert heading depending line on length; please delete delete. length; please delete other cover options once

Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy (all ages) NHS England Reference: P

GAMETE STORAGE. Reviewing body Review date Version no

Surgical Treatment for Movement Disorders

Clinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation

Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure. April Reference: NHSCB/A09/PS/a

Clinical Commissioning Policy Proposition: Tocilizumab for Giant cell arteritis (adults)

Specialised Services Policy Position PP104

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Skull Base Tumour Treatment NHS Overseas Programme (Adult)

Specialised Services Policy: CP23 Vagal Nerve Stimulation

Reference: NHS England: 16022/P

Clinical Commissioning Policy Statement: Flow Diverting Devices for Intracranial Aneurysms. April Reference : NHSCB/D03/PS/a

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

Stereotactic Radiosurgery/Fractionated Stereotactic Radiotherapy for Acoustic Neuroma (Vestibular Schwannomas)

You said we did. Our Healthier South East London. Dedicated engagement events

Clinical Commissioning Policy Statement: Co-careldopa Intestinal Gel (Duodopa) December Reference : NHSCB/D4/c/3

Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy

Specialised Services Policy:

Clinical Commissioning Policy: Arteriovenous Malformations. December Reference : NHSCB/D5/4

pat hways Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib157

Specialised Services Policy: CP28 Deep Brain Stimulation

NON MALIGNANT BRAIN TUMOURS Facilitator. Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol

1. POLICY: Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for Essential Tremor

Ablative procedures for the treatment of Parkinson s disease

pat hways Medtech innovation briefing Published: 16 May 2018 nice.org.uk/guidance/mib147

Clinical Commissioning Policy Proposition: Tocilizumab for Takayasu arteritis (adults)

General remarks on Neurorejuvenation Spinal Cord Stimulation (SCS) Program Occipital Nerve Stimulation Gamma-knife for Trigeminal Neuralgia

Reference: NHS England 1602

Imagine your tremor free life! Non-Invasive Treatment for Essential Tremor

Commissioning Policy Individual Funding Request

Surgical Treatment: Patient Edition

Clinical Commissioning Policy: Auditory brainstem implant with congenital abnormalities of the auditory nerves of cochleae

Deep Brain Stimulation: Indications and Ethical Applications

pat hways Medtech innovation briefing Published: 24 August 2016 nice.org.uk/guidance/mib76

Endobronchial valve insertion to reduce lung volume in emphysema

Specialised Services Policy Position PP151

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Pre-filled Patient Controlled Analgesia (PCA) syringes

Leksell Gamma Knife Icon. Treatment information

About Cancer Research UK

Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia

Cancer Survivorship NEURO-ONCOLOGY PATIENT SURVIVORSHIP PLAN. Resources and Tools for the Multidisciplinary Team

Clinical Commissioning Policy Proposition: Urethroplasty for benign urethral strictures in adult men

DEEP BRAIN STIMULATION

LOCAL EQUALITY ADVISORY FORUM (LEAF) A Staffordshire CCGs Equality & Inclusion Group. Terms of Reference

Policy Statement. Title/Topic: Hyaluronic Acid Injections for Osteoarthritis Date: April 2014 Reference: GM037

Specialised Services Commissioning Policy. CP29: Bariatric Surgery

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei

Clinical Commissioning Policy Proposition:

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015

Leicester City, East Leicestershire and Rutland & West Leicestershire Collaborative Commissioning Policy Gamete/Embryo cryopreservation

Smoke Free Policy. Version 2.0

Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache

Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist

NICE guidelines. Flu vaccination: increasing uptake in clinical risk groups and health and social care workers

Brain Tumor Treatment

Extracorporeal Shockwave Therapy (ESWT) and Radial Pulse Therapy (RPT) August 2016

None Natalia Clifford, Public Health Consultant Tel: Summary

UNPRECEDENTED BENEFITS TRANSFORMATIVE RESULTS. In clinical studies, patients reported an immediate, significant reduction of tremor.

EMERGING TREATMENTS FOR PARKINSON S DISEASE

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents

Key uncertainties around the evidence or technology are that the test has only been validated in biochemical studies.

Barnet Scrutiny Committee report 13 th October Barnet Sexual Health Strategy Dr Andrew Howe, Director of Public Health

Clinical Commissioning Policy Proposition: Deep Brain Stimulation for Refractory Tourette Syndrome in adults

Surgical Treatment of Movement Disorders. Surgical Treatment of Movement Disorders. New Techniques: Procedure is safer and better

National Institute for Health and Clinical Excellence

Commissioning Policy. Hernia Repair in Adults. Criteria Based Access. Date Adopted: 22 nd December 2017 Version:

Clinical Commissioning Policy Proposition: 18Fflourodeoxyglucose

Medical technologies guidance Published: 2 October 2018 nice.org.uk/guidance/mtg39

Surgical Options. A History of Surgical Treatment. Patient selection. Essential Tremor (ET)

Primary brain tumours and cerebral metastases workshop

Clinical Commissioning Policy: Stereotactic Radiosurgery / Radiotherapy For Cerebral Metastases. December Reference : NHSCB/D5/1

Clinical Commissioning Policy Proposition:

A Patient s Guide to SRS

The innovative aspects are that the test automatically generates a report on ALK status that any clinician can interpret.

Understanding. Tremor. Christy, diagnosed with essential tremor in childhood, with her husband, Ben.

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Shaheen Shaikh, M.D. Assistant Professor of Anesthesiology, University of Massachusetts Medical center, Worcester, MA.

Transcription:

Clinical Commissioning Policy Proposition: Stereotactic Radiosurgery (SRS) for adults with Parkinson's tremor and Familial Essential Tremor Version Number: NHS England B13X06/01

Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over, with Publications Gateway reference number assigned after it has been cleared by the Publications Gateway Team. Publications Gateway guidance and the IRB can be found on the Intranet. 1

Clinical Commissioning Policy Proposition: Stereotactic Radiosurgery (SRS) for adults with Parkinson's tremor and Familial Essential Tremor First published: February 2016 Prepared by NHS England Specialised Commissioning Team Published by NHS England, in electronic format only. 2

Contents Equality Statement 4 Plain Language Summary 4 1. Introduction 5 2. The proposed intervention and clinical indication 5 3. Definitions 5 4. Aim and objectives 6 5. Epidemiology and needs assessment 6 6. Evidence base 7 7. Documents which have informed this policy proposition 8 8. Date of review 8 3

Equality Statement NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation. Plain Language Summary Movement disorders including Parkinson's disease and familial essential tremor (FET) can severely affect the ability of a patient to undertake activities of daily living (eating, shopping, brushing teeth etc.). Whilst medications can be used to control unwanted movements, sometimes these are ineffective or the side effects prevent the medicaiton being used and so further interventions need to be considered. Lesional surgery, the process of destroying the brain tissue causing the uncontrolled movements, has mostly been replaced with the use of deep brain stimulation (DBS) which can be adjusted in response to a patient's symptoms. SRS is another method by which the area of the brain causing the uncontrolled movements can be destroyed. NHS England has concluded that there is not sufficient evidence to routinely commission SRS for drug-resistant movement disorders. 4

1. Introduction This document describes the evidence that this been considered by NHS England in formulating a proposal to not routinely commission stereotactic radiosurgery (SRS) for Parkinson's tremor and familial essential tremor. For the purpose of consultation NHS England invites views on the evidence and other information that has been taken into account as described in this policy proposition. A final decision as to whether SRS for drug-resistant movement disorders will be routinely commissioned is planned to be made by NHS England by June 2016 following a recommendation from the Clinical Priorities Advisory Group. 2. The proposed intervention and clinical indication The basic principle of stereotactic radiosurgery (SRS) is the elimination of a functional disorder, or destruction of abnormal tissues, by administration of a strong and highly focused dose of radiation. The procedure allows radiation to be limited to the targeted area and thus helps spare the surrounding tissues as much as possible. SRS is routinely used in the treatment of a number of different brain and central nervous system pathologies as defined by a number of clinical commissioning pathways. Here, we consider the use of SRS as the final treatment option for patients with drug resistant tremor associated with Parkinson s disease and familial essential tremor (FET). 3. Definitions For the purpose of this policy the term SRS is used to mean treatment given as a single fraction. SRS is a highly conformal radiotherapy treatment to a precisely delineated target volume, delivered using stereotactic localisation techniques. A multidisciplinary team of neurosurgeons, neuro-oncologists and neuro-radiologists are involved in SRS case selection, treatment planning and delivery. Parkinson's disease is a chronic disease of the brain which may occur when the brain does not produce enough dopamine, a chemical it needs to perform certain functions. This affects the brain's ability to control movement and other muscle functions and is characterised by gradually worsening tremor, muscle rigidity and difficulties with starting and stopping movements. The condition is usually treated with drugs. Surgery can be considered in people who have responded poorly to drugs, who have severe side-effects from medication, or who have severe fluctuations in response to drugs (on-off syndrome). Essential tremor is a progressive neurological condition that causes a trembling of the hands, head, voice, legs, or trunk. It is not caused by loss of dopamine. Essential tremor has familial tendency, people with familial essential tremor (FET) may get it earlier in life than those with non-familial or sporadic essential tremor. Severe tremor can be disabling because it affects fine-movement coordination. Tremor can be treated by rehabilitation and drug therapy, and early appropriate treatment may minimise functional disability. Antitremor drugs reduce the amplitude but not the frequency of tremor, and this does not always translate into functional improvement. Due to the side-effect profile of anti-tremor medications, there are some cases where the dose required to effectively control the 5

medications, there are some cases where the dose required to effectively control the tremor causes unacceptable side effects, worsening the patient's quality of life. Lesional surgery, which often involves ablation of the thalamic nucleus, is reserved for patients with severe disabling tremor and functional disability that interferes with activities of daily living, and for tremor that is refractory to the highest tolerated doses of medication. Surgery of this nature is currently routinely commissioned and has a significant evidence base. Due to the degenerative nature of Parkinson's disease, the anticipated benefits acquired by undergoing SRS can relapse, in contrast to essential tremor where SRS outcomes remain permanent. Usual surgical care of drug-resistant Parkinson's disease and FET will continue to be deep brain stimulation and thalamotomy. SRS represents a different tool by which to make a lesion in the area of the brain responsible for the uncontrolled movements. 4. Aim and objectives The policy aims to define NHS England's commissioning position on stereotactic radiosurgery for the treatment of patients with movement disorders associated with Parkinson s disease and familial essential tremor. The objective is to ensure evidence based commissioning with a view to improving outcomes for patients with movement disorders. 5. Epidemiology and needs assessment Parkinson's disease affects 0.5% of the population aged 65-74 and 1-2% of the population over 75. Of this patient cohort, 90-99% of patients will respond to medications, leaving a small group of patients suitable for brain surgery. Deep brain stimulation will remain the preferred choice of brain surgery for these patients. Estimations of the incidence and prevalence of tremor vary widely as a mild degree of tremor is a very common finding affecting between 2-4% of the population. More unusual is to have a tremor severe enough to interfere with activities of daily living, necessitating surgical intervention. One functional neurosurgery practice estimates that tremor surgery (deep brain stimulation) is being offered to one patient in 400,000-500,000. The majority of interventions for tremor will continue to be deep brain stimulation, due to the flexibility that this device offers, or alternatively thalamotomy. The remaining patients that would be eligible to receive stereotactic radiosurgery is estimated at less than 10 patients per year nationwide. 6

6. Evidence base NHS England has concluded that there is not sufficient evidence to support a proposal for the routine commissioning of SRS for drug-resistant Parkinson's tremor and familial essential tremor. We conclude there is low level evidence (level 3) to support the use of stereotactic radiosurgery in the treatment for movement disorders. In conclusion there is insufficient evidence for efficacy, safety, impact on quality of life and cost effectiveness. To date there has been no randomised trial comparing stereotactic radiosurgery with any other treatment modality such as deep brain stimulating and/or radiofrequency ablation. Stereotactic radiosurgery has been reserved for patients with intractable tremor, where more invasive surgical therapies are contraindicated. Two recent prospective studies (level 3) have reported a significant improvement in activities of daily living (ADL). Witjas et al (2015) reported a 72.2% improvement (0-100%) in ADL and Ohye et al (2012) reported 81.1% patients rating a tremor score as excellent or good post stereotactic radiosurgery. The largest case series (level 3) within the last five years by Kooshkabadhi et al, 2013 (n=88) showed at least 81% improvement in at least one of the three tremor scores. These two prospective studies have also evaluated the size of the thalamic lesion pre and post radiation with brain MRI scans, with an overall expected lesion response in the majority of patients. However, authors have noted the thalamic site can fluctuate and warrants further investigation. Witjas et al (2015), described one patient (n=50) with an extensive thalamic response that spontaneously resolved. The results of these three cases series are consistent with a recent systematic review by Campbell et al, 2015 (level -2). The review evaluated 29 papers of which were primarily case reports and patient case series. Sixteen studies evaluated tremor scores pre and post stereotactic radiosurgery, patient numbers in the studies varied from 172 to 8. All studies except one study showed an improvement in tremor score, range of improvement from 50-100%. Overall the systematic review concluded approximately 80% of patients with intractable tremor had some clinical benefit following the procedure. The review identified the largest case series, conducted by Young et al 2010 (n=172) which showed an improvement in both drawing and writing scores (P<0.001), at 6 month follow-up. The three recent cases series (Witjas et al (2015), Ohye et al (2012) and Kooshkabadhi (2013)) describe at least one patient developing transient contralateral weakness following SRS therapy, which resolved spontaneously. No other significant side effects were reported. In the systematic review (Campbell et al, 2015) complication rate reported varied between 0% -16 %, predominately motor symptoms. In the review, one group reported a thalamic haemorrhage at treatment site, although the patient was on anticoagulant treatment. In addition three groups in the review reported patient deaths attributed to the therapy. One patient developed aspiration pneumonia secondary to dysphagia, one died of radiation necrosis (bilateral lesions), one died of haemorrhagic stroke at site of lesion 7.5 years after procedure. One group described a correlation between lesion seize and dose in Gy. The authors concluded on the basis of the systematic review unilateral gamma knife thalamotomy using doses from 130-150 Gy is well tolerated and safe. However to date there has not been a long term follow-up study and requires further investigation. 7

there has not been a long term follow-up study and requires further investigation. We found no specific evidence relating to the model of care post-srs that may impact on the long term duration of response, for example input from other specialities such as occupational health, physiotherapy. 7. Documents which have informed this policy proposition Publications Gateway Reference 02469 / Sterotactic Radiosurgery and Radiotherapy Services - Needs assessment and Service Review, NHS England / November 2014 8. Date of review This document will lapse upon publication by NHS England of a clinical commissioning policy for the proposed intervention that confirms whether it is routinely or non-routinely commissioned (expected by June 2016) 8